|
May 15
|
INVO Reports Record First Quarter 2024 Financial Results
|
|
Apr 16
|
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Dec 6
|
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
|
|
Nov 28
|
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
|
|
Aug 9
|
INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
|
|
Aug 8
|
INVO Bioscience Announces Closing of $4.5 Million Public Offering
|
|
Aug 4
|
INVO Bioscience Announces Pricing of $4.5 Million Public Offering
|